Geron (GERN) updates Clinical Data from GRNOPC1 Spinal Cord Injury Trial
Proactive Investors USA & Canada
The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. There is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, ...
Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury TrialMarketWatch (press release)

all 13 news articles »